Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from SAB Biotherapeutics ( (SABS) ) is now available.
On April 28, 2026, SAB Biotherapeutics entered into a five-year Master Manufacturing Services Agreement with Emergent BioSolutions Canada for clinical and commercial manufacturing of its SAB-142 product at Emergent’s Canadian facility. Emergent receives the sole and exclusive manufacturing right for SAB-142 during the term, with SAB Biotherapeutics permitted to secure alternative manufacturing only in limited circumstances when Emergent cannot or will not supply.
The agreement’s term begins upon potential future FDA approval of SAB-142 and runs for five years thereafter, with a minimum aggregate spend commitment of $36 million following such approval. Termination provisions include insolvency, non-payment, material breach, mutual agreement, or extended force majeure, and in certain Emergent-initiated terminations SAB Biotherapeutics must pay remaining minimum annual spend, underscoring a significant long-term financial and operational commitment around SAB-142’s prospective commercialization pathway.
The most recent analyst rating on (SABS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
Spark’s Take on SABS Stock
According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.
The score is held down primarily by weak financial performance (revenue collapse, ongoing operating losses, and persistent cash burn). Technicals and valuation are more neutral-to-supportive (price modestly above key moving averages and a low P/E), while corporate updates are net positive due to encouraging early clinical signals and added funding—tempered by shareholder dilution risk.
To see Spark’s full report on SABS stock, click here.
More about SAB Biotherapeutics
SAB Biotherapeutics, Inc. is a biotechnology company focused on developing drug candidates such as SAB-142. The company operates in the biopharmaceutical manufacturing and development space, relying on external partners for clinical and commercial-scale production of its pipeline products to support regulatory approval and market entry strategies.
Average Trading Volume: 562,332
Technical Sentiment Signal: Sell
Current Market Cap: $176.8M
For detailed information about SABS stock, go to TipRanks’ Stock Analysis page.